2XRA image
Entry Detail
PDB ID:
2XRA
Keywords:
Title:
crystal structure of the HK20 Fab in complex with a gp41 mimetic 5- Helix
Biological Source:
PDB Version:
Deposition Date:
2010-09-13
Release Date:
2010-12-15
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Free:
0.27
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:TRANSMEMBRANE PROTEIN GP41
Chain IDs:A
Chain Length:228
Number of Molecules:1
Biological Source:SYNTHETIC CONSTRUCT
Polymer Type:polypeptide(L)
Description:HK20, HUMAN MONOCLONAL ANTIBODY HEAVY CHAIN
Chain IDs:B (auth: H)
Chain Length:223
Number of Molecules:1
Biological Source:HOMO SAPIENS
Polymer Type:polypeptide(L)
Description:HK20, HUMAN MONOCLONAL ANTIBODY LIGHT CHAIN
Chain IDs:C (auth: L)
Chain Length:215
Number of Molecules:1
Biological Source:HOMO SAPIENS
Primary Citation
Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.
PLoS Pathog. 6 e1001195 e1001195 (2010)
PMID: 21124990 DOI: 10.1371/journal.ppat.1001195

Abstact

The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by targeting the highly conserved heptad repeat 1 (HR1) of gp41, which is transiently exposed during HIV-1 entry. Here we present the crystal structure of the HK20 Fab in complex with a gp41 mimetic 5-Helix at 2.3 Å resolution. HK20 employs its heavy chain CDR H2 and H3 loops to bind into a conserved hydrophobic HR1 pocket that is occupied by HR2 residues in the gp41 post fusion conformation. Compared to the previously described HR1-specific mAb D5, HK20 approaches its epitope with a different angle which might favor epitope access and thus contribute to its higher neutralization breadth and potency. Comparison of the neutralization activities of HK20 IgG, Fab and scFv employing both single cycle and multiple cycle neutralization assays revealed much higher potencies for the smaller Fab and scFv over IgG, implying that the target site is difficult to access for complete antibodies. Nevertheless, two thirds of sera from HIV-1 infected individuals contain significant titers of HK20-inhibiting antibodies. The breadth of neutralization of primary isolates across all clades, the higher potencies for C-clade viruses and the targeting of a distinct site as compared to the fusion inhibitor T-20 demonstrate the potential of HK20 scFv as a therapeutic tool.

Legend

Protein

Chemical

Disease

Primary Citation of related structures